Migraine Drugs Update: What You Need to Know - 1 AMA PRA Category 1 Credits

Subject areas

This course counts toward the state boards and subject areas below.

Disclosure statements

ACCME Activity ID 202583621

Upon completion of this activity, the participant will be able to:

1. Explain the current approach to the management of migraines.
2. Discuss the pharmacologic options available for acute and preventive treatment of migraine and compare them based on their efficacy, dosage and administration, potential adverse effects, and drug interactions.
3. Determine the most appropriate therapy given the individual presentation of a patient with migraine.
4. Explore the effectiveness of oral nonopioid analgesics, such as acetaminophen or nonsteroidal anti-inflammatory drugs (NSAIDs), in addressing mild to moderate migraine pain. Evaluate the benefits and limitations of nonopioid analgesics as an initial treatment approach, emphasizing their role in achieving effective relief while minimizing potential side effects.
5. Recognize the potential risks and drawbacks associated with the use of butalbital- or opioid-containing products for migraine treatment. Gain insights into why these products are not recommended, understanding the rationale behind avoiding their use in the management of migraine pain.
6. Discuss the pivotal role of triptans as the drug of choice for addressing moderate to severe migraine pain in patients without vascular disease. Explore the mechanisms of action and unique characteristics of triptans that make them the preferred pharmacologic option in specific migraine scenarios.
7. Examine the similarities and differences among the shorter-acting oral triptans, including sumatriptan, almotriptan, eletriptan, rizatriptan, and zolmitriptan. Evaluate their efficacy, speed of onset, and duration of action, providing a comprehensive understanding of the nuances that may influence the selection of a specific triptan based on individual patient needs.
8. Explore the faster-acting characteristics of intranasal triptan formulations in comparison to oral triptans. Assess the advantages and considerations associated with subcutaneous sumatriptan, acknowledging its effectiveness while being mindful of potential adverse effects. Understand the nuanced decision-making process in selecting the most appropriate triptan formulation based on patient factors and clinical considerations.
9. Examine the efficacy and potential applications of CGRP receptor antagonists and the 5-HT1F receptor agonist lasmiditan in migraine management. Understand their role as alternative options, particularly in patients with vascular disease, while acknowledging their relative effectiveness compared to triptans.
10. Explore the use of neuromodulatory devices as a potential option when pharmacotherapy is not a feasible or effective choice. Understand the circumstances under which neuromodulatory devices may be considered, providing a broader perspective on treatment modalities for migraine cases that do not respond to traditional pharmacotherapy.

This CME activity was planned and produced in accordance with the ACCME Essentials and Policies through the joint providership of The Medical Letter and AchieveCE. The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Learner Feedback